Targeting regulatory T cells as a new mode of immunotherapy

• PhD
• Graduate Research Masters
• Masters by Coursework
• Honours

Immunotherapy is revolutionising cancer treatment by training our immune system to target and destroy cancer cells with precision, offering hope for patients. However, 60-70% of patients do not respond, highlighting the need for innovative approaches.

Regulatory T (Treg) cells are an exciting target for immunotherapy. In tumour microenvironments, Treg cells block effective anti-cancer responses and are linked to poor prognosis. Blocking Treg cells remains challenging, as whole-body reduction causes autoimmune side effects. This project aims to uncover tumour-specific Treg survival pathways, allowing precise targeting of tumour Treg cells without harming healthy tissues.

This project is ideal for students interested in immunology and cancer research. You will gain exposure to various techniques, including multi-dimensional flow cytometry, in vivo cancer models, and the analysis of human samples.

The Gray Lab investigates the molecular control of cell death processes shaping immune responses. Our recent discoveries have elucidated the molecular control of Treg cell survival, offering the possibility to target these pathways in multiple diseases, including cancer.

Located within the Immunology Division, our team comprises highly collaborative and passionate post-doctoral scientists, research assistants, and PhD students with diverse backgrounds. We provide a unique, collaborative environment and opportunities to develop diverse skill sets and make impactful discoveries.

Our notable publications include:
Teh et al, Science Immunology 2022
Teh et al, Blood Advances 2022
Teh et al, Cell Death and Differentiation 2020